First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay -- ...

First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Same-restaurant sales growth of 7.1%Total revenues increased 25.6%Net income of $3.0 million and Adjusted EBITDA of $34.1 million21 new system-wide restaurants opened in 14 states BRADENTON, Fla., Nov ...

Total Revenue Increased 2% Sequentially Delivered $0.35 AFFO Per Share Reiterated 2025 Full-Year Outlook ATLANTA, GA, Nov. 06, 2025 (GLOBE ...

JERSEY CITY, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- AvePoint (NASDAQ: AVPT, SGX: AVP), the global leader in data security, governance and resilience, today announced financial results for the third ...

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...